Journal article
Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor–Initiating Cells
Abstract
PURPOSE: Clonal evolution of cancer may be regulated by determinants of stemness, specifically self-renewal, and current therapies have not considered how genetic perturbations or properties of stemness affect such functional processes. Glioblastoma-initiating cells (GICs), identified by expression of the cell surface marker CD133, are shown to be chemoradioresistant. In the current study, we sought to elucidate the functional role of CD133 in …
Authors
Venugopal C; Hallett R; Vora P; Manoranjan B; Mahendram S; Qazi MA; McFarlane N; Subapanditha M; Nolte SM; Singh M
Journal
Clinical Cancer Research, Vol. 21, No. 23, pp. 5324–5337
Publisher
American Association for Cancer Research (AACR)
Publication Date
December 1, 2015
DOI
10.1158/1078-0432.ccr-14-3147
ISSN
1078-0432
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AC133 AntigenAnimalsAntigens, CDAntineoplastic AgentsBrain NeoplasmsCell ProliferationCell Self RenewalDisease Models, AnimalGene ExpressionGene Expression ProfilingGene Expression Regulation, NeoplasticGene Knockdown TechniquesGene Regulatory NetworksGlioblastomaGlycoproteinsHumansNeoplastic Stem CellsPeptidesPrognosisPyrvinium CompoundsSignal TransductionSpheroids, CellularTumor Cells, CulturedXenograft Model Antitumor Assays